Abstract
Over the last decade, we have seen great progress in the treatment of malignant melanoma. Both in metastatic disease and in the adjuvant regime.
Eleven new drugs or combinations for the treatment of malignant melanoma are currently registered. Successes in the treatment of malignant melanoma are inextricably linked to the understanding of molecular processes in the pathogenesis of malignant melanoma and due to the identification of key structures controlling the the immune response.
There are basically two approaches: immunotherapy and targeted therapy. Both of these directions prove effective.
The pitfalls of all cancer therapy are the risks associated with treatment. This is especially emphasized in the case of adjuvant treatment.
However, despite these risks, these two treatments are the only meaningful way to treat malignant melanoma.